ridinilazole对中日韩艰难拟梭菌临床株的抗菌活性评估
该研究用琼脂稀释法检测ridinilazole及6种对照药物对日本64株、韩国32株、中国44株艰难拟梭菌的体外活性。所有菌株对ridinilazole敏感(MIC 0.03–0.25 mg/L),但RT 017和RT 369等多重耐药常见,提示需持续监测耐药谱。
要点
- ridinilazole对中日韩艰难拟梭菌临床株均有强体外活性,MIC低至0.03–0.25 mg/L。
- RT 017多重耐药突出:克林霉素100%、莫西沙星91.3%、利福昔明82.6%耐药。
- 亚洲菌株对对照药耐药常见,需持续监测耐药谱以控制耐药株传播。
核心结论
- ridinilazole对来自日本、韩国和中国的艰难拟梭菌临床株表现出强效抗菌活性。
- 受试菌株对多种对照抗菌药物普遍耐药,尤其RT 017和RT 369等多重耐药谱常见。
研究设计与样本
- 采用琼脂稀释法测定ridinilazole及6种对照药物对艰难拟梭菌临床株的体外敏感性。
- 纳入日本64株、韩国32株、中国44株艰难拟梭菌临床株。
主要发现
- 所有菌株均对ridinilazole敏感,MIC范围为0.03–0.25 mg/L。
- RT 017菌株中克林霉素耐药100%、莫西沙星耐药91.3%、利福昔明耐药82.6%。
- RT 369菌株中克林霉素耐药94.4%、莫西沙星耐药100%。
- 日本所有菌株均未检出利福昔明耐药。
- 对克林霉素、莫西沙星和利福昔明三重耐药见于19株RT 017(中国和韩国)、2株RT 001(韩国)和1株RT 046(韩国)。
临床怎么用
- ridinilazole体外对亚洲艰难拟梭菌株活性强,可作为潜在治疗选择关注。
- 临床应关注RT 017等多重耐药株的流行,并结合本地耐药监测数据指导用药。
局限性
- 仅纳入日本、韩国和中国部分临床株,样本量有限,代表性需进一步验证。
- 研究为体外药敏试验,未报告临床疗效或体内数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clostridioides difficile is the most common cause of antimicrobial-associated diarrhoea in high-income countries. Fluoroquinolone resistance enabled the emergence and intercontinental spread of the epidemic ribotype (RT) 027 strain of C. difficile in the early 2000s. Despite frequent inappropriate antimicrobial use in Asia, RT 027 is rarely isolated in the region, but the often fluoroquinolone- and clindamycin-resistant RT 017 strain predominates. OBJECTIVES: This study evaluated the antimicrobial activity of ridinilazole, a novel antimicrobial agent with highly specific activity for C. difficile, against clinical strains of C. difficile from Asia. METHODS: C. difficile strains from Japan (n = 64), South Korea (n = 32) and China (n = 44) were tested by the agar dilution method for susceptibility to ridinilazole, metronidazole, vancomycin, clindamycin, moxifloxacin, rifaximin and fidaxomicin. RESULTS: All strains were susceptible to ridinilazole, with low MICs (0.03-0.25 mg/L). Several strains showed multiresistance profiles, particularly RT 017 (100% clindamycin resistant, 91.3% moxifloxacin resistant, 82.6% rifaximin resistant) and RT 369 (94.4% clindamycin resistant, 100% moxifloxacin resistant). Rifaximin resistance was absent in all strains from Japan. Multiresistance to clindamycin, moxifloxacin and rifaximin was found in 19 RT 017 strains (from China and South Korea), 2 RT 001 strains (South Korea) and 1 RT 046 strain (South Korea). CONCLUSIONS: Ridinilazole showed potent activity against a range of Asian C. difficile strains, which otherwise frequently displayed resistance to several comparator antimicrobial agents. Ongoing surveillance of antimicrobial resistance profiles is required to monitor and control the spread of resistant strains.
引用
- Collins DA, Wu Y, Tateda K, et al. Evaluation of the antimicrobial activity of ridinilazole and six comparators against Chinese, Japanese and South Korean strains of Clostridioides difficile. J Antimicrob Chemother. 2021. PMID: 33351917. doi:10.1093/jac/dkaa522
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。